Fondaparinux reversal with activated prothrombin complex concentrate in anesthetised bleeding rats

Thrombosis and Haemostasis

Volumn 109, Issue 3, 2013, Pages 560-563

  Corbonnois, Gilles ^a,b   Martin, Michèle ^a,b   Hacquard, Marie ^a   Levy, Bruno ^b,c   Mertes, Paul Michel ^a,b   Lecompte, Thomas ^a,b,d   Audibert, Gérard ^a,b  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b INSERM   (France)

^c UNIVERSITÉ DE LORRAINE   (France)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; FONDAPARINUX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; TRANEXAMIC ACID;

ANIMAL EXPERIMENT; BLEEDING; CONTROLLED STUDY; DRUG MEGADOSE; LETTER; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; THROMBIN TIME;

ANESTHESIA; ANIMALS; ANTICOAGULANTS; ARTERIES; BLOOD PRESSURE; FACTOR VIIA; HEMORRHAGE; HEMOSTASIS; MALE; POLYSACCHARIDES; PROTHROMBIN; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; THROMBIN; TIME FACTORS;

EID: 84874773352     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-08-0575     Document Type: Letter

References (25)

1. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e419S-494S.
2. Hamm CW, Bassand J-P, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999-3054.
3. Bauer KA. Reversal of antithrombotic agents. Am J Hematol 2012; 87 (Suppl 1): S119-126.
4. Bianchini EP, Fazavana J, Picard V, et al. Development of a recombinant antithrombin variant as a potent antidote to fondaparinux and other heparin derivatives. Blood 2011; 117: 2054-2060.
5. Lisman T, Bijsterveld NR, Adelmeijer J, et al. Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux. J Thromb Haemost 2003; 1: 2368-2373.
6. Gerotziafas GT, Depasse F, Chakroun T, et al. Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood. Thromb Haemost 2004; 91: 531-537.
7. Desmurs-Clavel H, Huchon C, Chatard B, et al. Reversal of the inhibitory effect of fondaparinux on thrombin generation by rFVIIa, aPCC and PCC. Thromb Res 2009; 123: 796-798.
8. Bijsterveld NR, Moons AH, Boekholdt SM, et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002; 106: 2550-2554.
9. Elg M, Carlsson S, Gustafsson D. Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthesized rats and rabbits. Thromb Res 2001; 101: 159-170.
10. Ryan KL, Cortez DS, Dick EJ, et al. Efficacy of FDA-approved hemostatic drugs to improve survival and reduce bleeding in rat models of uncontrolled hemorrhage. Resuscitation 2006; 70: 133-144.
11. Hemker HC, Giesen P, Al Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
12. Hacquard M, Perrin J, Lelievre N, et al. Inter-individual variability of effect of 7 low molecular weight antithrombin-dependent anticoagulants studied in vitro with calibrated automated thrombography. Thromb Res 2011; 127: 29-34.
13. Elg M, Carlsson S, Gustafsson D. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor. Thromb Res 2001; 101: 145-157.
14. Dickneite G. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation. Thromb Res 2007; 119: 643-651.
15. Staszyk C, Bohnet W, Gasse H, Hackbarth H. Blood vessels of the rat tail: a histological re-examination with respect to blood vessel puncture methods. Lab Anim 2003; 37: 121-125.
16. Smogorzewska A, Brandt JT, Chandler WL, et al. Effect of fondaparinux on coagulation assays: results of College of American Pathologists proficiency testing. Arch Pathol Lab Med 2006; 130: 1605-1611.
17. Gatt A, van Veen JJ, Woolley AM, et al. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro. Thromb Haemost 2008; 100: 350-355.
18. Crowther MA, Warkentin TE. Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood 2008; 111: 4871-4879.
19. Luu H, Ewenstein B. FEIBA safety profile in multiple modes of clinical and home-therapy application. Haemophilia 2004; 10 (Suppl 2): 10-16.
20. Turecek PL, Váradi K, Schwarz HP. Update on the mechanism of action and future of activated prothrombin complex concentrates. Curr Hematol Rep 2004; 3: 331-337.
21. Aledort LM. Factor VIII inhibitor bypassing activity (FEIBA)-addressing safety issues. Haemophilia 2008; 14: 39-43.
22. Nagler M, Haslauer M, Wuillemin WA. Fondaparinux-data on efficacy and safety in special situations. Thromb Res 2012; 129: 407-417.
23. Huvers F, Slappendel R, Benraad B, et al. Treatment of postoperative bleeding after fondaparinux with rFVIIa and tranexamic acid. Neth J Med 2005; 63: 184-186.
24. Luporsi P, Chopard R, Janin S, et al. Use of recombinant factor VIIa (NovoSeven®) in 8 patients with ongoing life-threatening bleeding treated with fondaparinux. Acute Card Care 2011; 13: 93-98.
25. Godier A, Durand M, Emmerich J, et al. Efficacy of prothrombin complex concentrate to reverse the anticoagulant effect of the pentasaccharide fondaparinux in a rabbit model. Thromb Haemost 2011; 105: 161-168.